Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Alector Inc
ALEC | US
1.95
USD-0.12
-5.80%
ALEC | US
About Alector Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.95
Open
2.04
High
2.07
Low
1.92
Alector Inc. a clinical stage biopharmaceutical company develops therapies for the treatment of neurodegeneration diseases. Its products include AL001 an immune activity in the brain with genetic links to multiple neurodegenerative disorders which is in Phase III clinical trial for the treatment of frontotemporal dementia Alzheimer's Parkinson's and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases including Alzheimer's and Parkinson's diseases. The company also offers AL002 a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003 which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A a risk gene for Alzheimer's disease. Alector Inc. has a collaboration agreement with Adimab LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies such as AL001 AL002 and AL101 to treat neurodegenerative diseases. Alector Inc. was founded in 2013 and is headquartered in South San Francisco California.
View LessALEC | US
Risk
75.7
Sharpe
0.41
Luna's Score
37/100
Recommendation
Sell
Luna says (ALEC | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
45.0%1 month
75.7%3 months
78.0%6 months
71.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
526.32
Price to book
3.36
Debt to equity
0.24
Debt to assets
0.06
Ent. to EBITDA
-8.40
Ent. to rev.
0.70
PEG
-
Other Fundamentals
EBITDA
-181.60M
MarketCap
189.78M
MarketCap(USD)
189.78M
Div. yield
-
Op. margin
-302.37
Erngs. growth
-86.30
Rev. growth
-73.20
Ret. on equity
-92.64
Short ratio
7.19
Short perc.
6.07
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.40
Range1M
0.78
Range3M
0.85
Volumes: Market Activity
Rel. volume
2.23
Price X volume
3.04M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -8.40 | - | Cheaper |
| Ent. to Revenue | 0.70 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.36 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 78.02 | - | Par |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 189.78M | - | Emerging |
